BIIB vs. BMY
Compare and contrast key facts about Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: BIIB or BMY.
Correlation
The correlation between BIIB and BMY is 0.29, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
BIIB vs. BMY - Performance Comparison
Key characteristics
BIIB:
-1.63
BMY:
0.57
BIIB:
-2.45
BMY:
1.11
BIIB:
0.72
BMY:
1.14
BIIB:
-0.62
BMY:
0.34
BIIB:
-1.75
BMY:
1.41
BIIB:
23.67%
BMY:
11.55%
BIIB:
25.42%
BMY:
28.56%
BIIB:
-90.24%
BMY:
-70.62%
BIIB:
-66.52%
BMY:
-23.77%
Fundamentals
BIIB:
$21.95B
BMY:
$116.92B
BIIB:
$11.06
BMY:
-$3.58
BIIB:
6.24
BMY:
1.92
BIIB:
$9.41B
BMY:
$47.44B
BIIB:
$6.75B
BMY:
$33.40B
BIIB:
$2.90B
BMY:
$5.06B
Returns By Period
In the year-to-date period, BIIB achieves a -43.27% return, which is significantly lower than BMY's 16.38% return. Over the past 10 years, BIIB has underperformed BMY with an annualized return of -7.86%, while BMY has yielded a comparatively higher 2.39% annualized return.
BIIB
-43.27%
-7.06%
-34.37%
-41.68%
-13.42%
-7.86%
BMY
16.38%
0.07%
42.98%
14.59%
1.32%
2.39%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
BIIB vs. BMY - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Dividends
BIIB vs. BMY - Dividend Comparison
BIIB has not paid dividends to shareholders, while BMY's dividend yield for the trailing twelve months is around 4.22%.
| TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BIIB Biogen Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 6.98% | 0.00% | 0.00% | 0.00% | 0.00% |
BMY Bristol-Myers Squibb Company | 4.22% | 4.44% | 3.00% | 2.36% | 3.69% | 2.55% | 3.08% | 2.55% | 1.95% | 2.17% | 2.46% | 3.31% |
Drawdowns
BIIB vs. BMY - Drawdown Comparison
The maximum BIIB drawdown since its inception was -90.24%, which is greater than BMY's maximum drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for BIIB and BMY. For additional features, visit the drawdowns tool.
Volatility
BIIB vs. BMY - Volatility Comparison
Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY) have volatilities of 6.29% and 6.37%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Financials
BIIB vs. BMY - Financials Comparison
This section allows you to compare key financial metrics between Biogen Inc. and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities